Straightforward Surgery Advances Drug Delivery To The Brain

Adopting an established endoscopic nasal grafting technique, researchers at Mass Eye and Ear have shown the ability to deliver a drug across the blood-brain barrier effectively and with reduced side effects. Their work could move rapidly into clinical testing in neurodegenerative diseases and could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.

Adopting an endoscopic nasal grafting technique used in tumor excision and to plug leaks resulting from herniated tissue in the nose, a team led by Benjamin Bleier, MD, a surgeon at the Massachusetts Eye & Ear Infirmary, a part of Harvard Medical School, has shown the ability to deliver glial-derived neurotrophic factor (GDNF) across the blood-brain barrier effectively and with reduced side effects. Their work thus far has been in a mouse model. But it could move rapidly into clinical testing in neurodegenerative diseases given the already-established regulatory pathway for GDNF and the established nature of the skull-based surgery. Also, while GDNF may offer a practical route to proof-of-concept, the technique could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.

For many years, clinicians have contemplated drug delivery to the brain by spraying compounds into the nose, based on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.